(Reuters) - Rigel Pharmaceuticals Inc said its experimental drug failed to meet the main goal in a mid-stage study in patients with dry eye disease. Rigel said it had decided not to initiate new studies of R348 for this indication, but was continuing a mid-stage study of the drug in dry eye patients with graft versus host disease. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment